Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
Business24 hours ago3 reasons to buy this surging ASX 200 stock today
-
Business21 hours agoThis ASX dividend stock could be primed for a rebound
-
Noosa News18 hours agoQantas Has Just Announced a Huge International Sale, Featuring Return Flights on 30-Plus Routes Starting From $499
-
Noosa News22 hours agoBrisbane news LIVE updates: Two meteor showers to light up Brisbane sky | Young man dies after six-vehicle crash